RecruitMe Clinical Trial

Randomized Phase 2 Study of Neoadjuvant Nivolumab with and without Urelumab in Cisplatin-Ineligible Patients with Muscle-Invasive Urothelial Carcinoma of the Bladder
Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Sponsor:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR7552
U.S. Government ID:NCT02845323
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this research study will have participants either take Nivolumab in combination with Urelumab or Nivolumab alone.

Do You Qualify?
Are you at least 18 years of age?YesNo
Do you have muscle-invasive urothelial carcinoma of the bladder?YesNo
Submit
Cancel
Investigator
Christopher Anderson, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162